Liminal BioSciences is a Canadian biopharmaceutical company focused on discovering and developing small molecule therapeutics for metabolic, inflammatory, and fibrotic diseases. The company uses a data-driven drug discovery approach and has emphasized programs that modulate GPCR pathways. Its pipeline strategy is centered on developing differentiated candidates for diseases with meaningful unmet clinical need and partnership potential.